Chinese Journal of Antituberculosis ›› 2021, Vol. 43 ›› Issue (9): 905-909.doi: 10.3969/j.issn.1000-6621.2021.09.009
• Original Articles • Previous Articles Next Articles
Received:
2021-07-15
Online:
2021-09-10
Published:
2021-09-07
Contact:
CHU Nai-hui
E-mail:dongchu1994@sina.com
SHI Wen-hui, CHU Nai-hui. Resistance to fluoroquinolones and the influencing factors in patients with drug-resistant pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2021, 43(9): 905-909. doi: 10.3969/j.issn.1000-6621.2021.09.009
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2021.09.009
影响因素 | 敏感(557例) | 耐药(431例) | χ2值 | P值 | ||
---|---|---|---|---|---|---|
年龄组(岁) | 6.154 | 0.013 | ||||
<18 | 17(3.05) | 4(0.93) | ||||
18~34 | 215(38.60) | 141(32.71) | ||||
35~64 | 283(50.81) | 253(58.70) | ||||
>65 | 42(7.54) | 33(7.66) | ||||
性别 | 0.619 | 0.431 | ||||
男性 | 403(72.35) | 302(70.07) | ||||
女性 | 154(27.65) | 129(29.93) | ||||
治疗分类 | 43.453 | <0.01 | ||||
初治 | 206(36.98) | 77(17.86) | ||||
复治 | 351(63.02) | 354(82.14) | ||||
利福平耐药 | 25.968 | <0.01 | ||||
是 | 470(84.38) | 408(94.66) | ||||
否 | 87(15.62) | 23(5.34) | ||||
氟喹诺酮类药物用药史 | 0.465 | 0.495 | ||||
有 | 15(2.98) | 15(3.81) | ||||
无 | 488(97.02) | 379(96.19) | ||||
影响因素 | 敏感(557例) | 耐药(431例) | χ2值 | P值 | ||
肺部基础疾病 | 0.840 | 0.360 | ||||
有 | 45(8.08) | 42(9.74) | ||||
无 | 512(91.92) | 389(90.26) | ||||
居住地 | 37.508 | <0.01 | ||||
北京 | 175(31.42) | 63(14.62) | ||||
非北京 | 382(68.58) | 368(85.38) |
变量 | β值 | s | Wald χ2值 | P值 | OR(95%CI)值 |
---|---|---|---|---|---|
年龄组(以“>65岁组”为参照) | |||||
<18岁 | 1.324 | 0.708 | 3.503 | 0.061 | 0.266(0.066~1.064) |
18~34岁 | 0.171 | 0.294 | 0.338 | 0.561 | 0.843(0.474~1.499) |
35~64岁 | 0.101 | 0.283 | 0.129 | 0.720 | 1.107(0.636~1.926) |
男性 | 0.091 | 0.157 | 0.333 | 0.564 | 0.913(0.671~1.243) |
初治 | 0.911 | 0.179 | 25.927 | <0.01 | 0.402(0.283~0.571) |
利福平耐药 | 0.995 | 0.273 | 13.313 | <0.01 | 2.704(1.585~4.615) |
有氟喹诺酮类药物用药史 | 0.979 | 0.402 | 5.922 | 0.015 | 2.661(1.210~5.854) |
有肺部基础疾病 | 0.257 | 0.248 | 1.075 | 0.300 | 0.773(0.475~1.257) |
居住在北京 | 0.889 | 0.18 | 24.517 | <0.01 | 0.411(0.289~0.585) |
[1] | World Health Organization. Global tuberculosis report 2020. Geneva:World Health Organization, 2020. |
[2] |
Chen TC, Lu PL, Lin CY, et al. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis, 2011, 15(3):e211-e216. doi: 10.1016/j.ijid.2010.11.008.
doi: 10.1016/j.ijid.2010.11.008 URL |
[3] |
Sulochana S, Mitchison DA, Kubendiren G, et al. Bactericidal activity of moxifloxacin on exponential and stationary phase cultures of Mycobacterium tuberculosis. J Chemother, 2009, 21(2):127-134. doi: 10.1179/joc.2009.21.2.127.
doi: 10.1179/joc.2009.21.2.127 pmid: 19423464 |
[4] |
Li Y. China’s misuse of antibiotics should be curbed. BMJ, 2014, 348:g1083. doi: 10.1136/bmj.g1083.
doi: 10.1136/bmj.g1083 URL |
[5] |
Zhang Z, Lu J, Wang Y, et al. Prevalence and molecular chara-cterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. Antimicrob Agents Chemother, 2014, 58(1):364-369. doi: 10.1128/AAC.01228-13.
doi: 10.1128/AAC.01228-13 URL |
[6] |
Wei X, Zou G, Yin J, et al. Comparing patient care seeking pathways in three models of hospital and TB programme collaboration in China. BMC Infect Dis, 2013, 13:93. doi: 10.1186/1471-2334-13-93.
doi: 10.1186/1471-2334-13-93 URL |
[7] |
Hu Y, Liu J, Shen J, et al. Genotyping and molecular characterization of fluoroquinolone’s resistance among multidrug-resistant Mycobacterium tuberculosis in Southwest of China. Microb Drug Resist, 2021, 27(7):865-870. doi: 10.1089/mdr.2019.0339.
doi: 10.1089/mdr.2019.0339 URL |
[8] |
Javaid A, Hasan R, Zafar A, et al. Pattern of first- and second-line drug resistance among pulmonary tuberculosis retreatment cases in Pakistan. Int J Tuberc Lung Dis, 2017, 21(3):303-308. doi: 10.5588/ijtld.16.0444.
doi: 10.5588/ijtld.16.0444 pmid: 28225340 |
[9] |
Kuo CY, Wang WH, Huang CH, et al. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment. J Microbiol Immunol Infect, 2018, 51(1):88-93. doi: 10.1016/j.jmii.2017.05.008.
doi: 10.1016/j.jmii.2017.05.008 URL |
[10] |
Liu CH, Yang N, Wang Q, et al. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital. Respirology, 2011, 16(6):918-925. doi: 10.1111/j.1440-1843.2011.01990.x.
doi: 10.1111/j.1440-1843.2011.01990.x URL |
[11] |
Vashakidze L, Salakaia A, Shubladze N, et al. Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. Int J Tuberc Lung Dis, 2009, 13(9):1148-1153.
pmid: 19723406 |
[12] |
Kliiman K, Altraja A. Predictors of extensively drug-resistant pulmonary tuberculosis. Ann Intern Med, 2009, 150(11):766-775. doi: 10.7326/0003-4819-150-11-200906020-00004.
doi: 10.7326/0003-4819-150-11-200906020-00004 pmid: 19487711 |
[13] |
Suárez-García I, Rodríguez-Blanco A, Vidal-Pérez JL, et al. Risk factors for multidrug-resistant tuberculosis in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis, 2009, 28(4):325-330. doi: 10.1007/s10096-008-0627-y.
doi: 10.1007/s10096-008-0627-y URL |
[14] |
Malik S, Willby M, Sikes D, et al. New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. PLoS One, 2012, 7(6):e39754. doi: 10.1371/journal.pone.0039754.
doi: 10.1371/journal.pone.0039754 URL |
[15] |
高谦, 梅建. 传播才是造成我国结核病高耐药率的主要原因. 中国防痨杂志, 2015, 37(11):1091-1096. doi: 10.3969/j.issn.1000-6621.2015.11.002.
doi: 10.3969/j.issn.1000-6621.2015.11.002 |
[16] |
Punga VV, Jakubowiak WM, Danilova ID, et al. Prevalence of extensively drug-resistant tuberculosis in Vladimir and Orel regions, Russia. Int J Tuberc Lung Dis, 2009, 13(10):1309-1312.
pmid: 19793439 |
[17] |
Prammananan T, Arjratanakool W, Chaiprasert A, et al. Second-line drug susceptibilities of Thai multidrug-resistant Mycobacterium tuberculosis isolates. Int J Tuberc Lung Dis, 2005, 9(2):216-219.
pmid: 15732744 |
[1] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[2] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[3] | Yang Ziyi, Chen Suting. Research progress on bedaquiline resistance and drug resistance diagnosis [J]. Chinese Journal of Antituberculosis, 2025, 47(3): 374-379. |
[4] | Li Xuelian, Zhang Hongyan, Wang Jun, Wang Qingfeng, Ma Liping, Chu Naihui, Nie Wenjuan. Safety of extended delamanid use in drug-resistant tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 164-168. |
[5] | Xu Zian, Pu Feifei, Feng Jing, Xia Ping. Research progress of high-throughput sequencing technology in the diagnosis and treatment of osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(2): 224-230. |
[6] | Zhang Lifan, Chen Yan, Zhang Yueqiu, Zhang Fengchun, Zeng Xiaofeng, Zhao Yan, Liu Shengyun, Zuo Xiaoxia, Zhang Zhiyi, Wu Huaxiang, Chen Sheng, Li Hongbin, Zhu Ping, Wu Lijun, Qi Wencheng, Liu Yi, Zhang Miaojia, Liu Huaxiang, Zhou Baotong, Shi Xiaochun, Ruan Guiren, Liu Xiaoqing, The Epidemiological Study and Therapeutic Evaluation of Rheumatic Patients with Tuberculosis Study Team. Prevalence of active tuberculosis in Chinese patients with rheumatic diseases: A multicenter cross-sectional subgroup analysis [J]. Chinese Journal of Antituberculosis, 2025, 47(1): 22-28. |
[7] | Geng Zimei, Wang Chaohong, Long Sibo, Zheng Maike, Shi Yiheng, Sun Yong, Zhao Yan, Wang Guirong. Analysis of bacteriological positivity and rifampicin resistance in patients with severe pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1050-1055. |
[8] | Wang Fei, Hua Duo, Guo Jianjian, Liu Chang, Han Lu, Ren Yi. Characteristic analysis of non-tuberculous mycobacterial pulmonary disease patients in Wuhan area from 2021 to 2023 [J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1069-1076. |
[9] | Yang Liangzi, Zhang Peize, Lu Shuihua. Interpretation of World Health Organization’s Co-administration of Treatment for Drug-resistant Tuberculosis and Hepatitis C: 2024 Update [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 874-876. |
[10] | Xue Yi, Liang Qian, Qi Haoran, Liang Ruixia, Huang Hairong. Reliability analysis of rifampicin-resistance detected by different diagnostics as a predictor for multidrug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 892-896. |
[11] | Yu Lan, Chen Shuangshuang, Wang Nenhan, Tian Lili, Zhao Yanfeng, Fan Ruifang, Liu Haican, Li Chuanyou, Dai Xiaowei. Consistency between phenotypic resistance to fluoroquinolones and genetic mutations in rifampicin resistant Mycobacterium tuberculosis strains [J]. Chinese Journal of Antituberculosis, 2024, 46(8): 942-950. |
[12] | Gao Lei, Liang Yaxue, Liu Shengsheng, Wang Hua. Analysis of treatment outcomes and influencing factors in 144 elderly patients with rifampicin drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2024, 46(7): 799-807. |
[13] | Zhang Hongtai, Ren Yixuan, Hu peilei, Wang Nenhan, Li Jie, Tian Lili, Zhao Yanfeng, Chen Shuangshuang, Li Chuanyou. Comparison of microbiota diversity in the sputum of pulmonary tuberculosis patients with rifampicin resistance or sensitivity [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 625-633. |
[14] | Du Yuhua, Feng Yajuan, Lei Yu, Lai Keng, He Weiyun. Analysis of the detection and treatment of rifampicin-resistant pulmonary tuberculosis patients in Guangzhou during the “12th Five-Year Plan” and “13th Five-Year Plan” periods [J]. Chinese Journal of Antituberculosis, 2024, 46(6): 678-686. |
[15] | Ye Xinchun, Liu Saiduo, Cheng Fang, Jiang Xiangao, Ning Hongye, Wu Zhengxing, Zhou Yueying, Qiu Chaochao, Pan Ning, Shi Jichan. Risk factors of latent tuberculosis infection among close contacts of drug-resistant pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2024, 46(5): 525-530. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||